
PRECIGEN, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Precigen is a biopharmaceutical company that develops gene and cell therapies, using synthetic biology platforms to design treatments for cancers and other diseases, including its lead program for recurrent respiratory papillomatosis.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| KINDLER JEFFREY BDirector | Sell | $1.38M | 185,000at $7.44 | Aug 26, 2026 |
| AGEE NANCY HDirector | Buy | $25K | 3,411at $7.23 | Aug 21, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PGEN activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.